Publications, Pharmaceutical

Developing More Sustainable pMDIs: A Q&A on Motivation, Progress and Challenges

Although pMDIs account for only a small fraction of global warming, more sustainable pMDIs are an important goal for pharmaceutical companies and healthcare providers alike, especially with the global phase down of F-gas use. In this interview, Chris Baron, Director of Business Development (Pulmonary) for Aptar Pharma considers the need for more sustainable pMDIs, progress towards the identification and use of alternative propellants and the challenges associated with reformulation.

Patient choice and preference are key when it comes to treating respiratory diseases such as asthma and COPD, with poor adherence rates compromising patient outcomes. More sustainable pMDIs will safeguard cost-effective provision of the rescue and maintenance medications that patients currently rely on and use effectively, while at the same time reducing the environmental burden of treatment. Implications for formulation and device design are discussed with reference to the two leading candidates for propellant substitution – P152a and HFO 1234ze. The evolving regulatory framework and propellant supply landscape are also considered along with the potential impact and contribution of newer technologies such as breath actuated inhalers and digital healthcare solutions.

For more information on PMPS (Pharmaceutical Manufacturing and Packing Sourcer).

Download Publication on Inhalers and Their Environmental Impact
Author(s): Chris Baron
19 Apr 2023

Learn more about Inhalation Drug Delivery

Find Out More about Inhalation Drug Delivery

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Market Insights

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
22 Apr 2024

Navigating the Shift to more sustainable Low GWP propellants in pMDIs

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
26 Mar 2024

Optimizing Preclinical Studies for Intranasal and Pulmonary Programs

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations

Read More
1 2 3 19

Request Access

Close

Requesting access to Developing More Sustainable pMDIs: A Q&A on Motivation, Progress and Challenges.

  • This field is for validation purposes and should be left unchanged.
Back To Top